We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+26.04%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$25M
Cap. Flow
+$13.4M
Cap. Flow %
8.63%
Top 10 Hldgs %
52.92%
Holding
50
New
18
Increased
7
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$8.77M
2
PODD icon
Insulet
PODD
+$8.67M
3
ILMN icon
Illumina
ILMN
+$7.24M
4
LAB icon
Standard BioTools
LAB
+$6.75M
5
BNR
Burning Rock Biotech
BNR
+$5.15M

Top Sells

Rank Stock Value
1
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$5.71M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$5.31M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$5.3M
4
CNC icon
Centene
CNC
+$4.92M
5
SAGE
Sage Therapeutics
SAGE
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
26
Arcus Biosciences
RCUS
$3.66B
$2.21M 1.42%
129,042
+77,968
+153% +$1.74M
FSDC
27
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$2.17M 1.39%
+193,728
New +$2.07M
JAZZ icon
28
Jazz Pharmaceuticals
JAZZ
$16.7B
$1.63M 1.05%
+11,447
New +$1.42M
ITOS
29
DELISTED
iTeos Therapeutics
ITOS
$1.43M 0.92%
+57,751
New +$1.55M
CALC icon
30
CalciMedica
CALC
$10.4M
$1.17M 0.75%
+6,583
New +$1.37M
ELDN icon
31
Eledon Pharmaceuticals
ELDN
$284M
$1.03M 0.66%
+60,495
New +$596K
PMVP icon
32
PMV Pharmaceuticals
PMVP
$65.6M
$884K 0.57%
+24,892
New +$916K
EQ icon
33
Equillium
EQ
$138M
$828K 0.53%
+143,543
New +$1.16M
RNAC icon
34
Cartesian Therapeutics
RNAC
$265M
$137K 0.09%
+1,845
New +$141K
BIO icon
35
Bio-Rad Laboratories Class A
BIO
$9.48B
– –
-6,434
Closed -$2.9M
BLUE
36
DELISTED
bluebird bio
BLUE
– –
-1,930
Closed -$1.53M
BNTX icon
37
BioNTech
BNTX
$23.3B
– –
-38,626
Closed -$2.58M
CNC icon
38
Centene
CNC
$32.9B
– –
-77,402
Closed -$4.92M
DNTH icon
39
Dianthus Therapeutics
DNTH
$6.25B
– –
-13,191
Closed -$1.58M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
– –
-234,753
Closed -$3.54M
CYPH
41
Cypherpunk Technologies Inc
CYPH
$72.4M
– –
-90,073
Closed -$1.88M
NXTC icon
42
NextCure
NXTC
$31.3M
– –
-4,038
Closed -$1.04M
PTCT icon
43
PTC Therapeutics
PTCT
$6.23B
– –
-73,708
Closed -$3.74M
RAPT
44
DELISTED
RAPT Therapeutics
RAPT
– –
-4,332
Closed -$1.01M
TWST icon
45
Twist Bioscience
TWST
$7.83B
– –
-53,344
Closed -$2.42M
UBX
46
DELISTED
Unity Biotechnology
UBX
– –
-12,018
Closed -$1.04M
GRTS
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-222,817
Closed -$1.48M
MRNS
48
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-146,561
Closed -$1.49M
AIMT
49
DELISTED
Aimmune Therapeutics
AIMT
– –
-100,544
Closed -$1.68M
MNTA
50
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-159,197
Closed -$5.3M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Asymmetry Capital Management held 50 positions worth $156M, up 19% from $131M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Asymmetry Capital Management deployed $13.4M of net new capital in Q3 2020, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was QuidelOrtho: 39,314 shares worth $8.63M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Bristol-Myers Squibb Company Contingent Value Rights, an estimated $5.71M trimmed.

  • Asymmetry Capital Management's largest Q3 2020 buy was QuidelOrtho: 39,314 shares worth $8.63M.
  • Asymmetry Capital Management added most to Ascendis Pharma A/S in Q3 2020, an estimated $4.86M increase.
  • Asymmetry Capital Management's biggest Q3 2020 reduction was Bristol-Myers Squibb Company Contingent Value Rights, cutting an estimated $5.71M.
  • Asymmetry Capital Management fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $5.3M.
  • Asymmetry Capital Management's ten largest holdings make up 53% of its $156M portfolio in Q3 2020.
  • Asymmetry Capital Management opened 18 new positions and closed 16 in Q3 2020.
  • Asymmetry Capital Management's portfolio value rose 19% quarter-over-quarter to $156M.

Based on Asymmetry Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.